Get the Stockscreener App
5.11
3.22%
-0.17
Pre-market:
5.13
0.02
+0.39%
Aligos Therapeutics Inc stock is traded at $5.11, with a volume of 86,807.
It is down -3.22% in the last 24 hours and down -10.51% over the past month.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
See More
Previous Close:
$5.28
Open:
$5.3
24h Volume:
86,807
Relative Volume:
0.44
Market Cap:
$31.62M
Revenue:
$4.71M
Net Income/Loss:
$-90.32M
P/E Ratio:
-0.5871
EPS:
-8.7032
Net Cash Flow:
$-85.19M
1W Performance:
+3.02%
1M Performance:
-10.51%
6M Performance:
-57.42%
1Y Performance:
-33.72%
1-Day Range:
$5.09
$5.40
1-Week Range:
$4.91
$5.55
52-Week Range:
$4.80
$13.69
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Name
Aligos Therapeutics Inc
Sector
Industry
Phone
(800) 466-6059
Address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
5.11 | 31.62M | 4.71M | -90.32M | -85.19M | -8.7032 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-26 | Resumed | Jefferies | Buy |
| Aug-18-25 | Resumed | H.C. Wainwright | Buy |
| Aug-19-24 | Initiated | H.C. Wainwright | Buy |
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-06-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-23-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-09-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Resumed | Piper Sandler | Overweight |
| Nov-10-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Initiated | JP Morgan | Overweight |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Aligos Therapeutics Inc Stock (ALGS) Latest News
Aligos Therapeutics (ALGS) Slides 8% – Support Test on the Horizon?Factor Rotation - newsline.com
Aligos Therapeutics Inc (ALGS) Stock Price, Quote, News & History - Benzinga
Lake Street Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Aligos Therapeutics (ALGS) Gets a Buy from Cantor Fitzgerald - The Globe and Mail
How (ALGS) Movements Inform Risk Allocation Models - Stock Traders Daily
Cantor Fitzgerald reiterates Aligos stock Overweight on HBV data By Investing.com - Investing.com Nigeria
Aligos’ ALG-215007 candidate ASO for HDV infection - BioWorld News
Cantor Fitzgerald reiterates Aligos stock Overweight on HBV data - Investing.com
Lake Street Initiates Aligos Therapeutics(ALGS.US) With Buy Rating, Announces Target Price $45 - Moomoo
ALGS Initiated Coverage by Lake Street -- Price Target Announced at $45 - GuruFocus
Aligos Therapeutics stock initiated at Buy by Lake Street on HBV drug potential - Investing.com South Africa
Aligos Therapeutics (ALGS) Showcases Promising Data at EASL Cong - GuruFocus
Hepatitis B data: 40% on Aligos drug reach HBsAg level used for cure regimens - Stock Titan
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 - Investing News Network
Aligos Therapeutics Presents Positive Phase 1 Data for Pevifoscorvir Sodium at EASL Congress 2026, Suggesting Reduced cccDNA Reservoir in Chronic HBV Patients - Quiver Quantitative
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 - GlobeNewswire Inc.
ALGS Q1 2026 Earnings: Narrower-Than-Expected Loss as Aligos Therapeutics Advances PipelineRevenue Estimate Trend - newsline.com
Cantor Fitzgerald Initiates Aligos Therapeutics(ALGS.US) With Buy Rating, Announces Target Price $20 - Moomoo
ALGS Initiated Coverage by Cantor Fitzgerald -- Rating Set to Ov - GuruFocus
ALGS News | ALIGOS THERAPEUTICS INC (NASDAQ:ALGS) - ChartMill
Lawrence M. Blatt discloses 5.1% stake in Aligos Therapeutics (ALGS) - Stock Titan
Aligos (ALGS) Delivers Q1 2026 Beat — EPS $-2.21 vs $-2.27 ExpectedSocial Trade Signals - Newser
Woodline Partners reports 4.4% stake in Aligos Therapeutics (NASDAQ: ALGS) - Stock Titan
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 - The Manila Times
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at EASL Congress 2026 - Quiver Quantitative
Liver disease drug data: Aligos secures 10 EASL 2026 slots - Stock Titan
TradingKey - TradingKey
What you need to know before buying Aligos (ALGS) (Investor Concern) 2026-05-08Crowd Consensus Signals - newser.com
The operating leverage hidden in Aligos (ALGS) results | Q1 2026: EPS Exceeds ExpectationsTarget Revision - Newser
Aligos Therapeutics (NASDAQ:ALGS) Surges After Hours on Q1 Earnings Beat - ChartMill
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - Investing News Network
China HBV license adds cash as Aligos (NASDAQ: ALGS) faces going‑concern risk - Stock Titan
Aligos lands FDA Fast Track and a $25M China deal for HBV drug - Stock Titan
Earnings Preview: ALGS to Report Financial Results Post-market on May 07 - Moomoo
How Aligos Therapeutics Inc. (ALGS) Affects Rotational Strategy Timing - Stock Traders Daily
Aligos Therapeutics Inc expected to post a loss of $2.22 a shareEarnings Preview - TradingView
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026 - The Manila Times
Biotech Aligos will post first-quarter results after markets close May 7 - Stock Titan
[ARS] Aligos Therapeutics, Inc. SEC Filing - Stock Titan
Aligos Therapeutics says China pact puts HBV drug in focus amid trial updates - MSN
Aligos Therapeutics (Nasdaq: ALGS) details ESPP, auditor and pay votes - Stock Titan
Aligos’ licensing deal in China broadens trial scope, secures immediate $25m - MLex
Is Aligos (ALGS) overbought or oversold? (Drifts Higher) 2026-04-27Retail Flow - Newser
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Aligos Therapeutics Inc Stock (ALGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):